Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Acromegaly is often diagnosed late because symptoms are subtle. Serum IGF-I is the best screening test, OGTT confirms GH excess, and MRI localizes pituitary tumors. New AI and imaging tools may improve earlier detection.
A 2026 review shows that many patients with acromegaly remain symptomatic and functionally impaired despite biochemical control, underscoring the need for routine patient-reported outcomes and lower-burden, multidisciplinary care.
High-quality pituitary imaging is essential for diagnosing and managing acromegaly, localizing somatotroph adenomas, guiding surgery or radiotherapy, and reducing treatment-related harm. A standardized, tiered MRI-based approach improves ac
A comprehensive analysis of the cAMP-driven pathogenesis of non-familial somatotroph adenomas, exploring how GNAS mutations and DNA damage response pathways dictate clinical behavior and therapeutic sensitivity in acromegaly.